PharmacoEconomics and Outcomes News logo Adis International logo

Publisher: Adis International

Volume 1, Number 493, 2005-12-17
Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

< previous issue | next issue > | all issues

Short communication

AAP guidelines for UTIs in infants discussed
pp. 2-2(1)

Research article

Mandatory folate fortification of flour called for in the UK
pp. 2-2(1)

Atomoxetine adds up in ADHD
pp. 3-4(2)

Short communication

Should the UK NHS follow the US example going forward?
pp. 4-4(1)

Research article

A position statement on the management of type 1 or type 2 diabetes mellitus (DM) in pregnancy has been released
pp. 4-4(1)

Esomeprazole a cost-effective cure for reflux oesophagitis
pp. 5-5(1)

Patient compliance with the recommended use and maintenance of nebulisers is poor
pp. 5-5(1)

Short communication

Controlling high US healthcare costs imperative
pp. 5-5(1)

Measures to improve glycaemic control in DM prove worthwhile
pp. 6-6(1)

Research article

Indirect costs drive burden of affective disorders in Europe
pp. 6-6(1)

Remifentanil and propofol sedation cost saving in ICU
pp. 6-6(1)

Less pain in the pocket using postop bupivacaine + fentanyl
pp. 7-7(1)

Pregabalin improves on usual care in neuropathic pain
pp. 7-7(1)

Insulin detemir "good value for money" for type 1 DM in Austria
pp. 7-7(1)

Increasing alteplase treatment for ischaemic stroke economical
pp. 8-8(1)

Cost-effective strategies for managing Crohn's disease
pp. 8-8(1)

Escitalopram better value than generic paroxetine in Canada
pp. 8-8(1)

Obesity burden weighty issue in Germany
pp. 9-9(1)

Losartan a "cost-effective intervention" for hypertension
pp. 9-9(1)

Polypharmacy "all too common" in psychiatric disorders
pp. 9-9(1)

Clinical outcomes are similar for abciximab and eptifibatide in patients who undergo percutaneous coronary intervention (PCI), but abciximab is associated with greater costs
pp. 10-10(1)

Concomitant fenspiride worthwhile in chronic bronchitis
pp. 10-10(1)

Rosuvastatin well worth it for long-term CHD prevention
pp. 10-10(1)

Drug therapy after AMI on the rise
pp. 11-11(1)

Nebivolol worth it for selected patients with hypertension
pp. 11-11(1)

Nicotinic acid + statin therapy the go for raising HDL-cholesterol
pp. 11-11(1)

Cilostazol warranted for intermittent claudication in Scotland
pp. 11-11(1)

Heartburn takes its toll in Taiwan
pp. 12-12(1)

Unemployment drives high cost of schizophrenia in the US
pp. 12-12(1)

HPV vax + cervical cancer screening potentially cost effective
pp. 12-12(1)

Bimatoprost sees cost savings for glaucoma treatment in Italy
pp. 12-12(1)

Varicella vaccination of healthcare workers costly in Israel
pp. 13-13(1)

Guidelines decrease mortality from severe hospital-acquired pneumonia
pp. 13-13(1)

Despite a high standard of treatment for patients with depression in Germany, there is still room for improvement
pp. 13-13(1)

Short communication

The vast majority of US pharmacists (69%) believe that they should have the authority to refuse to dispense prescriptions for emergency contraception
pp. 13-13(1)

Research article

Darbepoetin alfa protocol cost saving in anaemia
pp. 14-14(1)

Rasagiline, entacapone dominate levodopa in Finland
pp. 14-14(1)

Targeted recruitment for HIV treatment programmes best in Zambia
pp. 14-14(1)

Psoriasis is not optimally managed in the primary-care setting
pp. 14-14(1)

Epoetin alfa cost effective in chemotherapy-induced anaemia
pp. 15-15(1)

Low-dose aspirin produces hearty cost savings in CHD prevention
pp. 15-15(1)

Complications from percutaneous coronary intervention costly
pp. 15-15(1)

Therapy costs for ED lower than predicted
pp. 16-16(1)

Hormone therapy (HT) is losing popularity among middle-aged women
pp. 16-16(1)

Anaemia-related costs bleeding resources
pp. 16-16(1)

Men account for almost half of OAB burden in Europe
pp. 16-16(1)

Felodipine/metoprolol substantially reduces BP without HRQOL loss
pp. 17-17(1)

Successful H. pylori eradication ups QOL in functional dyspepsia
pp. 17-17(1)

Long-term effect of chemo "reassuring" in breast cancer
pp. 17-17(1)

Short communication

Global patient safety to receive funding boost
pp. 18-18(1)

Funding committed to AIDS projects in Spain
pp. 18-18(1)

Wyeth Pharmaceuticals has entered into a $US32 million, 5-year contract with the Division of AIDS of the US National Institutes of Health (NIH), for the development of therapeutic HIV vaccines.
pp. 18-18(1)

The new generation arthritis treatment adalimumab [Humira] will be available fully funded for patients in New Zealand with severe rheumatoid arthritis from 1 January 2006
pp. 18-18(1)

PTC Therapeutics has been awarded a 2-year grant from the US FDA to support clinical development of their drug PTC 124.
pp. 18-18(1)

SSRI scripts reach all-time high in NZ despite safety advice
pp. 18-18(1)

With the identification of specific patient populations in which targetted antineoplastics show a clear benefit, the high price of these therapies will continue to be supported
pp. 19-19(1)

< previous issue | next issue > | all issues

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A